Daily Newsletter

02 November 2023

Daily Newsletter

02 November 2023

Embolx and Girlow announce global distribution partnership

Embolx intends to expand access to its Sniper microcatheter across Mexico, Central America, South America and the Caribbean.

Archana Rani November 02 2023

Minimally invasive medical devices maker Embolx has partnered with advanced medical equipment distributor Girlow USA to expand access to the former’s medical technologies into South America.

The partnership will involve the use of Girlow’s established distribution channels and network by Embolx to make its medical technologies, including the Sniper Balloon Occlusion Microcatheter, more easily accessible beyond the US and Europe.

It aligns well with Girlow's mission of providing healthcare professionals with access to advanced medical technologies.

The Sniper microcatheter has been designed to optimise embolic agent delivery to treat different types of cancer and benign prostatic hyperplasia.

The technology will allow healthcare professionals to accurately target cancerous tumours and improve treatment efficacy while reducing complications.

It is claimed to be one of Embolx's flagship products for embolic treatment procedures.

Through the partnership, Embolx intends to provide access to its Sniper microcatheter for healthcare workers and institutions across Mexico, South America, Central America and the Caribbean.

Embolx president and CEO Michael Allen said: “We are thrilled to partner with Girlow USA, a highly respected global distributor in the medical field. By combining our expertise, we can make significant strides in improving patient care on a global scale.”

Together, Embolx and Girlow are poised to impact patient care by delivering advanced solutions for healthcare professionals.

Is the healthcare industry ready to fully embrace the benefits of digitalization and AI?

The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close